{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-321663","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.398381+00:00","generated_at":"2026-05-16T12:59:15.697660+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru reports FY2025 net loss $22.7M, cash $15.8M; enobosarm Phase 2b PLATEAU to start Q1'26","bullets":["Net loss from continuing ops $15.7M ($1.07/sh) vs $35.3M ($2.61/sh) prior year; total net loss $22.7M ($1.55/sh).","Post year-end public offering net proceeds ~$23.4M; cash as of Sep 30, 2025 was $15.8M vs $24.9M prior year.","FDA confirmed enobosarm 3 mg acceptable; incremental weight loss of ≥5% placebo-corrected at 52 weeks acceptable primary endpoint for approval.","Phase 2b QUALITY: enobosarm 3 mg preserved 100% lean mass, reduced physical function decline (≥10% stair climb power) from 44.8% to 17.6% with semaglutide.","Phase 2b PLATEAU of enobosarm 3 mg + GLP-1 RA in 200 obesity patients starts Q1 2026; interim results Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-321663","json":"https://secwatch.observer/filing/0001193125-25-321663.json","markdown":"https://secwatch.observer/filing/0001193125-25-321663.md","text":"https://secwatch.observer/filing/0001193125-25-321663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/0001193125-25-321663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:59:15.697660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}